Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

Predictgyn. Development of new strategies for the individual management of gynecological cancer patients

The overall aim of this project is the development of new markers for diagnosis and prediction in gynecological cancers (endometrial and ovarian) and the validation of therapies targeting these patient populations.

Given the ambition of the project, we have defined a number of specific objectives, which are:

  • To establish a biorepository endometrial and ovarian cancer samples with clinicopathological follow-up data.
  • To identify and validate prognostic markers in ovarian cancer by transcriptomics and proteomics.
  • To identify and validate prognostic markers in endometrial cancer by proteomics.
  • To validate a biomarker panel for histological subtyping and the degree assessment of endometrial cancer tumors.
  • To study and validate the expression profile of prognostic biomarkers of ovarian and endometrial cancer by multiple immunofluorescence.
  • To determine prognosis and recurrence using stem cells markers and multiple immunofluorescence assays.
  • To validate new therapies for endometrial and ovarian cancer

Consortium between Ability Pharmaceuticals S.L, Oryzon Genomics Diagnóstico S.L. (ODX), Laboratorio Reig Jofré, S.A., Institut de Recerca Biomédica de Lleida. Fundació Privada Dr. Pifarré and Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca

Cofunded the Spanish Ministerio de Economía y Competitividadby by the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (RETOS)

ID: RTC-2015-3821-1

2015-2018